Herzinfarkt nach Rituximab: Zusammenhang nicht ausgeschlossen

Schlüsselwörter

Rituximab - koronarer Vasospasmus - Vaskulitis

Keywords

rituximab - coronary angiitis - vasculitis

• Literatur

• 1 Arenja N, Zimmerli L, Urbaniak P et al. Akuter Vorderwandinfarkt nach Rituximab. Dtsch Med Wochenschr 2016; 141: 500-503
• 2 Lee L, Kukreti V. Rituximab-induced coronary vasospasm. Case Rep Hematol 2012; 2012: 984986
• 3 Ke C, Khosla A, Davis MK et al. A case of coronary vasospasm after repeat rituximab infusion. Case Rep Cardiol 2015; 2015: 523149
• 4 Hazebroek MR, Kemna MJ, Schalla S et al. Prevalence and prognostic relevance of cardiac involvement in ANCA-associated vasculitis: Eosinophilic granulomatosis with polyangiitis and granulomatosis with polyangiitis. Int J Cardiol 2015; 199: 170-179
• 5 Pocivalnik M, Pätzold S, Dorr K et al. Fever of unknown origin with angina: an atypical presentation of polyangiitis with granulomatosis. Circulation 2013; 128: 279-280
• 6 Misra DP, Shenoy SN. Cardiac involvement in primary systemic vasculitis and potential drug therapies to reduce cardiovascular risk. Rheumatol Int 2016; [epub ahead of print]
• 7 Suppiah R, Judge A, Batra R et al. A model to predict cardiovascular events in patients with newly diagnosed Wegener’s granulomatosis and microscopic polyangiitis. Arthritis Care Res 2011; 63: 588-596
• 8 Specks U. Pro: Should all patients with anti-neutrophil cytoplasmic antibody-associated vasculitis be primarily treated with rituximab?. Nephrol Dial Transplant 2015; 30: 1083-1087
• 9 Kronbichler A, Jayne DR, Mayer G. Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis. Eur J Clin Invest 2015; 45: 346-368
• 10 Kronbichler A, Jayne DR. Con: Should all patients with anti-neutrophil cytoplasmic antibody-associated vasculitis be primarily treated with rituximab?. Nephrol Dial Transplant 2015; 30: 1075-1081